Conclusion of non-exclusive drug discount agreement for Oxycodone/Naloxone
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Oxycodon/Naloxon (ATC-Code nach WHO: N02AA55)
Score d'opportunité
Pourquoi ce score ?
Opportunité
10 / 100
Complexité
20 / 100
Facteurs de risque
The XML change notice confirms the procedure ended on 30.09.2026 due to an exclusive agreement. Participation after tha...
No minimum purchase volumes; actual revenue depends on unpredictable prescription patterns.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Weak opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2027
- Supply of Oxycodone/Naloxone pharmaceutical products under non-exclusive discount agreements.
- Agreement under §130a Abs. 8 SGB V via open-house model.
Afficher le résumé complet
This is an open-house model for non-exclusive drug discount agreements for Oxycodone/Naloxone (ATC N02AA55) with AOK PLUS. The procedure is not a public procurement under the directive but published for transparency. Key conflict: the XML change notice indicates the procedure ended early as of 30.09.2026 due to an exclusive agreement, while the structured data shows a deadline of 31.03.2027. No estimated value is provided. No procurement documents were analyzed beyond the notice.
Risques
The XML change notice confirms the procedure ended on 30.09.2026 due to an exclusive agreement. Participation after tha...
No minimum purchase volumes; actual revenue depends on unpredictable prescription patterns.
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered drugs.
- Confidentiality: absolute secrecy regarding the content of the agreement and discount rates.
Eligibility
- Submit self-declarations: no exclusion grounds (§§123,124 GWB) and compliance with Russia sanctions (EU Reg. 833/2014).
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive drug discount agreement for Oxycodone/Naloxone
Non-exclusive discount agreement for the active ingredient Oxycodone/Naloxone (ATC N02AA55). Open-house model with no minimum volume guaranteed. Performance in Dresden, Germany.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe Kurzbeschreibung
Afficher les données TED originales
Titre original du lot
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Oxycodon/Naloxon (ATC-Code nach WHO: N02AA55)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 03 Jun 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 383818-2026
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
10 / 100
Complexité
20 / 100
Facteurs de risque
The XML change notice confirms the procedure ended on 30.09.2026 due to an exclusive agreement. Participation after tha...
No minimum purchase volumes; actual revenue depends on unpredictable prescription patterns.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications